Sabrina Serani is a senior editor for Targeted Oncology. She specializes in oncology, immunotherapy, and radiation oncology, with a strong focus on healthcare administration and diagnostics within the healthcare system. Sabrina's work has been featured in AJMC - The American Journal of Managed Care, BobVila.com, Oncology Nursing News, OncLive, Cancer Network, and CURE Media Group.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Sabrina Serani's coverage is primarily focused on healthcare and pharmaceutical topics, with an emphasis on cancer treatment, FDA approvals, clinical studies, and cancer research. Her articles often cite data and press releases.
Given the nature of her articles, Sabrina would likely be interested in speaking with experts who can provide insights into new clinical studies or FDA approvals related to cancer treatment. Professionals involved in conducting these studies or clinicians working directly with patients undergoing these treatments could make good potential sources for her work.
Given the focus on healthcare and pharmaceuticals without a specific geographic scope mentioned, she may be open to engaging with experts from various locations as long as they have relevant insights into the topics she covers.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Sabrina Serani
No approved targeted therapies exist for KRAS mutations other than G12C; KRAS G12D comprises ~15% of KRAS-mutant NSCLC and ~5% of all NSCLC, rivaling METex14 and EGFR exon20ins prevalence. Phase 1 setidegrasib (ASP3082) at 600 mg weekly in previously treated KRAS G12D NSCLC yielded 36% partial responses, median PFS 8.3 months, and estimated 12-month OS 59%.
By: Sabrina Serani
At the recommended liso-cel dose, CR/CRi was 45% and ORR 86%, with median PFS 31.4 months and CR/CRi duration of response not reached at 24.8 months.
Therapeutic decision-making in NSCLC is increasingly predicated on comprehensive molecular profiling, reflecting the expanding set of actionable genomic drivers beyond histology-based classification. NCCN and ASCO guidelines support broad NGS testing for eligible metastatic patients to maximize detection of targetable alterations and optimize first-line regimen selection.
By: Ravi Salgia, Sabrina Serani
City of Hope's Dr Ravi Salgia on what it would truly take to cure stage IV non–small cell lung cancer and where oncology is headed next in the years ahead.
By: Sabrina Serani
Across 52 trials, effective postprogression access averaged 42% in control arms, implying many patients never received the class later proven to improve OS in subsequent lines. Tumor-type disparities were substantial, with the lowest postprogression effective-therapy rates in breast cancer, followed by prostate and lung cancers.
By: Sabrina Serani
Registry data from 5090 patients (2016–2025) showed bulky disease in 27%, predominantly nodal, with 36.2% of recorded cases exceeding 10 cm and wide subtype-to-subtype prevalence. Treatment selection differed by bulk status, favoring systemic chemotherapy over localized approaches overall, while DLBCL more often received chemo plus consolidative radiotherapy and Hodgkin lymphoma more intensive regimens.
By: Jonah Feldman, Sabrina Serani
Accelerated approval relied on significantly higher MRD-negative CR at 10^-5 by next-generation flow in patients achieving CR or better: 41% with IberDd vs 21% with DVd (P<.0001). EXCALIBER-RRMM enrolled patients with 1–2 prior lines, excluding anti-CD38–refractory or bortezomib-refractory disease; up to 10% had prior anti-CD38 exposure, with stratification by lines, age, and ISS.
Hormone receptor and HER2 assessment remains the cornerstone for breast cancer subtyping and initial systemic therapy selection across clinical settings. Expanded HER2-low and HER2-ultralow classifications increase access to antibody–drug conjugates beyond conventionally defined HER2-negative tumors.
By: Jonah Feldman, Sabrina Serani
FDA CBER Type C meeting will scrutinize statistical justification for pooled nonconcurrent published controls versus OST-400 natural history data to contextualize 2.5-year OS. Regulatory strategy targets accelerated-approval BLA by end-2026, with RMAT and rolling review dependent on comparator alignment; MHRA scientific advice may enable 2.5-year OS-based CMAA.
By: Jonah Feldman, Laila Alkhouli, Sabrina Serani
Marked inter-center heterogeneity was observed in assessment frequency, documentation, and organ-specific depth, with substantial drop-off in routine surveillance after the first posttransplant year.
